# US 11,026,906 B2 · Pharmaceutical quality strontium L-lactate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,026,906 B2
- Document ID: US11026906B2
- Status: Granted
- Kind: B2
- Application number: 16/580,551
- Filed: 2019-09-24
- Published: 2020-01-16
- Granted: 2021-06-08
- Earliest claimed: 2016-09-30
- Applicants: Deanna J. Nelson
- Inventors: Deanna J. Nelson
- Web page: https://patentgrep.com/patent/US11026906B2

## CPC

- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 33/24: Heavy metals; Compounds thereof
- A61K 33/241: Lead; Compounds thereof
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application relates to strontium L-lactate compositions and methods of use. The methods and compositions disclosed herein are particularly useful for providing bioavailable strontium to mammals and treating or preventing symptoms of bone and/or cartilage disorders.

## Claims

### Claim 1

A method of preparing a pharmaceutical quality strontium L-lactate composition comprising:
a. selecting an L-lactic acid having at most trace concentrations of metals selected from the group consisting of aluminum, arsenic, barium, calcium, cadmium, chromium, lead, mercury, and thallium;
b. selecting a strontium carbonate, strontium oxide, or strontium hydroxide having at most trace concentrations of metals selected from the group consisting of aluminum, arsenic, barium, calcium, cadmium, chromium, lead, mercury, and thallium;
c. dissolving the L-lactic acid in water to obtain a homogeneous 0.1 M solution;
d. adding portions of strontium carbonate, strontium oxide, or strontium hydroxide to the vessel containing the solution of L-lactic acid until a mass of said strontium salt equal to 0.45-0.55 mole equivalents of L-lactic acid has been added and agitating the reaction mixture until a homogeneous solution is obtained;
e. removing particulate from the reaction mixture by filtration or centrifugation to provide a clarified solution;
f. diluting the clarified solution with a water-miscible, aprotic organic solvent to form a precipitate; and
g. isolating the precipitate and drying to constant mass to provide a pharmaceutical quality strontium L-lactate composition, wherein said strontium L-lactate composition is characterized in having a strontium D-lactate content of less than about 3 weight percent strontium D-lactate.

### Claim 2 (depends on 1)

The method of claim 1, wherein said pharmaceutical quality strontium L-lactate composition is characterized in having a strontium D-lactate content of less than about 1 weight percent and less than 100 ppm each calcium and aluminum.

### Claim 3

A method of preparation of a pharmaceutical quality strontium L-lactate composition comprising:
a. selecting a water-soluble salt of L-lactic acid having at most trace concentrations of metals selected from the group consisting of aluminum, arsenic, barium, calcium, cadmium, chromium, lead, mercury, and thallium;
b. selecting a water-soluble strontium salt having at most trace concentrations of metals selected from the group consisting of aluminum, arsenic, barium, calcium, cadmium, chromium, lead, mercury, and thallium;
c. dissolving one mole equivalent of the water-soluble L-lactate in the minimum volume of water needed to obtain a homogeneous solution;
d. dissolving 0.45-0.55 mole equivalents of the water-soluble strontium salt in the minimum volume of water needed to obtain a homogeneous solution;
e. adding the strontium salt solution to the vessel containing the L-lactate solution and agitating until a homogeneous solution is obtained;
f. controlling the reaction temperature, solution pH, and reaction time to ranges sufficiently low to prevent racemization;
h. removing particulate from the reaction mixture by filtration or centrifugation to provide a clarified solution;
i. diluting the clarified solution with a sufficient volume of a water-miscible, aprotic organic solvent to form a precipitate; and
j. isolating the precipitate and drying to constant mass to provide a pharmaceutical quality strontium L-lactate composition, wherein said strontium L-lactate composition is characterized in having a strontium D-lactate content of less than about 3 weight percent strontium D-lactate.

### Claim 4 (depends on 3)

The method of claim 3, wherein said pharmaceutical quality strontium L-lactate composition is characterized in having less than 100 ppm each calcium and aluminum.

### Claim 5

A method of preparing a pharmaceutical quality strontium L-lactate composition comprising:
a. selecting an L-lactic acid having at most trace concentrations of metals selected from the group consisting of aluminum, arsenic, barium, calcium, cadmium, chromium, lead, mercury, and thallium;
b. selecting a strontium oxide having at most trace concentrations of metals selected from the group consisting of aluminum, arsenic, barium, calcium, cadmium, chromium, lead, mercury, and thallium;
c. dissolving the L-lactic acid in water to obtain a homogeneous 0.1 M solution;
d. adding portions of strontium oxide to the vessel containing the solution of L-lactic acid until a mass of strontium oxide equal to 0.45-0.55 mole equivalents of L-lactic acid has been added and agitating the reaction mixture until a homogeneous solution is obtained;
e. controlling the reaction temperature, solution pH, and reaction time to ranges sufficiently low to prevent racemization;
f. removing particulate from the reaction mixture by filtration or centrifugation to provide a clarified solution;
g. diluting the clarified solution with a sufficient volume of a water-miscible, aprotic organic solvent to form a precipitate; and
h. isolating the precipitate and drying to constant mass to provide a pharmaceutical quality strontium L-lactate composition, wherein said strontium L-lactate composition is characterized in having a strontium D-lactate content of less than about 3 weight percent strontium D-lactate.

### Claim 6 (depends on 1)

A composition comprising an effective amount of a pharmaceutical quality strontium L-lactate composition wherein said pharmaceutical quality strontium L-lactate composition is characterized in having less than about 3 weight percent strontium D-lactate and less than 100 ppm each calcium and aluminum wherein the pharmaceutical quality strontium L-lactate composition is prepared by the process according to claim 1.

### Claim 7 (depends on 6)

The composition of claim 6, wherein said pharmaceutical quality strontium L-lactate composition is characterized in having a strontium D-lactate content of less than about 3 weight percent.

### Claim 8 (depends on 6)

The composition of claim 6, wherein said composition is characterized in containing less than 100 ppm each of metals selected from the group consisting of arsenic, barium, cadmium, chromium, lead, mercury, and thallium.

### Claim 9 (depends on 6)

The composition of claim 6, wherein said composition further comprises a pharmaceutically acceptable vehicle, carrier, or diluent.

### Claim 10 (depends on 8)

The composition of claim 8, wherein the composition comprises a unit dose between about 10 mg to about 300 mg strontium.